Eisai To Distribute Ajinomoto Drugs In 11 Asian Nations Outside Japan
This article was originally published in PharmAsia News
Japan's Ajinomoto has arranged for Esai to distribute its Livact Granules (amino acid) hepatic liver cirrhosis drug in Asian countries outside Japan. The two companies also are discussing having Esai get approval for and distribute other Ajinomoto digestive system drugs abroad as part of the company's goal of a 20 percent sales increase. The Livact agreement calls for Esai to target nine countries: Cambodia, China, India, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Sri Lanka, Thailand and Vietnam. (Click here for more - a subscription may be required
You may also be interested in...
In the only device-related warning letter released by the US FDA this week, Avazo Healthcare was selling two COVID-19 antigen tests without approval, clearance or authorization from the agency.
A sharp decline in the number of in-person facility inspections has forced the FDA to consider creative techniques for remotely evaluating manufacturer compliance during the COVID-19 pandemic. This and other stories topped our list of most-read Medtech Insight articles in November.
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.